“Medical Cannabis and Cannabinoids” is a peer-reviewed journal offering an international forum to present and discuss recent advances in the rapidly developing field of medical cannabis and cannabinoids.
Marijuana use is prevalent both in states where it is legal to some degree and in states where it is not. However, evidence suggests that many physicians may be unprepared for this reality.
There’s no official endorsement of medical cannabis for dementia, but with or without scientific data, more and more people are willing to investigate cannabis to treat their loved ones.
Although it’s entitled “How Legalization Changed Humboldt County Marijuana,” Emily Witt’s article in the New Yorker is not about new plant varieties but about new social realities.
Eating mushrooms may reduce the risk of cognitive impairment, according to a study published in the Journal of Alzheimer’s Disease.
EPIDIOLEX®, a cannabidiol oral solution has been transferred to Schedule V, the lowest restriction classification, by the U.S. Drug Enforcement Administration. But CBD remains on Schedule I, due to its supposed abuse liability.
Dr. Ethan Russo’s research on the Grand Unified Theory (GUT) that discusses how cannabis-based treatment and nutritional approaches can address five conditions that are difficult to treat with conventional medicine.
In this seminal study, Dr. Dedi Meiri and his team from Israel enhance our knowledge of the content, effect, and variability of cannabinoids across 36 individual cannabis cultivars.
SCC Board Members oppose several key provisions JAMA wants the state medical boards to adopt.
The Society of Cannabis Clinicians developed a survey in 2011 that asked about patients’ responses to CBD-rich cannabis.
Researchers have discovered that CBD (Cannabidiol) is a very potent inhibitor of breast cancer metastasis. Doctors who monitor cannabis use by patients were bursting with questions during a talk by Sean McAllister, PhD, who has been studying the anti-cancer effects of cannabinoids in the laboratory.